Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer Metastatic
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- NCT04031872
- Testing
- LY3200882
- Sponsor
- The Netherlands Cancer Institute
Cancer Weight Loss
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients.
- Trial name
- NCT06937177
- Testing
- TCMCB07
- Where
- 26 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Endevica Bio
Metastatic Colorectal Cancer
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
Researchers are collecting more information to improve treatment of metastatic colorectal cancer (mCRC) with regorafenib. Metastatic colorectal cancer (mCRC) is a cancer that starts in the large bowel and involves the rectum (the…
- Trial name
- RE-SEARCH (NCT04920422)
- Testing
- No intervention
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer
This is a Phase II multi-center 2-sequential cohorts trial, designed to assess the objective response rate of two anti HER2 combination in advanced disease CRC patients harbouring an amplified HER2 tumor assessed according to…
- Trial name
- HERACLES (NCT03225937)
- Testing
- Trastuzumab, Lapatinib, Pertuzumab, trastuzumab-emtansine
- Where
- 7 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Renal Cell Cancer
A Study of ABT-751 in Patients With Renal Cell Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days.
- Trial name
- NCT00073112
- Testing
- ABT-751
- Where
- 23 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Abbott
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Colorectal Cancer (CRC)
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT06825624
- Testing
- HS-20093, Bevacizumab, 5-FU
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumors, Metastatic Colorectal Cancer
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
The purpose of this study is to establish the safety and tolerability of BKM120 when combined with mFOLFOX6 and to define the maximum tolerated dose of BKM120 in this combination in advanced solid tumors including metastatic…
- Conditions
- Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT01571024
- Testing
- BKM120, mFOLFOX6
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
DMMR Colorectal Cancer, Colon Cancer Stage I
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
The RESET C2 trial aims to introduce organ sparing treatment or watch-and-wait (WW) to patients with localized deficient mismatch repair (dMMR) colon cancer through use of neoadjuvant pembrolizumab.
- Conditions
- DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab
- Trial name
- RESET C2 (NCT07409844)
- Testing
- 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab
- Where
- Denmark
- Volunteers
- 152 people
- Sponsor
- Ismail Gögenur
Serrated Polyp, Colorectal Neoplasms
Increasing Serrated Polyp Detection With a Brief Awareness Training
In this non-randomized controlled trial, a semi-random group of Dutch endoscopist receive an oral training about the significance of serrated polyps.
- Trial name
- NCT03902899
- Testing
- Educational intervention (oral presentation)
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Colon Cancer
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival…
- Trial name
- CLAUDIA (NCT05534087)
- Testing
- mFOLFIRINOX-FOLFIRI intensified chemotherapy, FOLFOX or CAPOX adjuvant chemotherapy
- Where
- 13 sites in South Korea
- Volunteers
- 236 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer
Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5…
- Trial name
- POSIBA (NCT01276379)
- Testing
- FOLFIRI (m), FOLFOX-6 (m), Cetuximab
- Where
- 27 sites in Spain
- Volunteers
- 221 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Neoplasms
Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery
aimed at investigating the efficacy, safety, and clinical outcome of Medium-Calorie or standard-calorie total parenteral nutrition (TPN) for patients with gastrointestinal cancer undergoing surgery
- Trial name
- NCT01700062
- Testing
- Total Parenteral Nutrition (TPN)
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Colorectal Cancer
Comparison of Mechanical Bowel Preparation Versus Enema for Candidates to Colorectal Resection for Adenocarcinoma
The purpose of this study is to evaluate mechanical bowel preparation (MBP) with polyethylene glycol plus bowel enema versus bowel enema alone in patients candidates to colorectal resection for malignancy.
- Trial name
- MBP (NCT00940030)
- Testing
- mechanical bowel preparation, enema
- Where
- Italy
- Volunteers
- 440 people
- Sponsor
- European Institute of Oncology
Shared Decision Making, Colonic Polyp
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread.
- Conditions
- Shared Decision Making, Colonic Polyp, Decision Aids, Rectal Polyp
- Trial name
- NCT05776381
- Testing
- Shared Decision Making using a Patient Decision Aid.
- Volunteers
- 110 people
- Sponsor
- Vejle Hospital
Colorectal Cancer
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
- Trial name
- NCT00034619
- Testing
- ALIMTA, Oxaliplatin
- Where
- 22 sites in United States
- Sponsor
- Eli Lilly and Company
Recurrent Colon Cancer, Recurrent Rectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00138177
- Testing
- oxaliplatin, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer.
- Trial name
- NCT00096330
- Testing
- dietary intervention, folic acid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Carcinoma of the Appendix, Colorectal Cancer
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Carcinoma of the Appendix, Colorectal Cancer, Small Intestine Cancer
- Trial name
- NCT00019773
- Testing
- capecitabine, oxaliplatin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment
This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with metastatic…
- Trial name
- NCT07409805
- Testing
- YMN-136 Vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.